glp 1 receptor agonists are contraindicated in GLP-1 increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Ten Top Tips for the

Biomed Pharmacother 99:681687 Yu N, Chu C, Kunitake T, Kato K, Nakazato MKannan H, (2007) Cardiovascular actions of central neuropeptide W in conscious rats

These observations indicate the importance of additional investigations of long-term dementia risk

Endothelial cell experiments suggest BPC157 influences VEGFR2 signalling, FAK (focal adhesion kinase) pathways, Src family kinases and ERK1/2 signalling

These medications are not FDA-approved, and no claims are made regarding their safety, efficacy, or quality

Another syndrome is post-COVID-19 sarcopenia, characterized by loss of muscle mass and function [102], leading to exercise intolerance [8, 32]